Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing Weekly

Review of hedge fund launches, closures, trends, regulatory and legal events - week 18

Sunday, May 09, 2010

Benedicte Gravrand, Opalesque London:

Last week, we heard of fund launches from Vector (energy); Merrion (UCITS European L/S equity); Aberdeen (Ucits fund of absolute return funds); Pardus Capital (debt); Evolved Alpha (multi-strat); Dalton IM (high yield mortgage); IKOS (Ucits version of currency fund); and Auldyn Partners (global macro). HSBC wound up a listed FoHFs.

The HFRX Global Hedge Fund Index was up 0.80% (est.) in April (+2.45% YTD); Credit Suisse Liquid Alternative Beta Index went up 1.14% (2.99% YTD); and the UCITS HFS Index gained 0.90%.

HFR reported that capital flows to Asian hedge funds had stalled in Q1-10, reflecting continued concerns about strategic and regulatory risks: total assets invested increased to $77bn and the number of Asian hedge funds declined modestly to 1,036; it was also reported that Hong Kong hedge funds DragonBack saw its assets cut by 85%, and Northwest double to $680m.

During Q1-10, BlackRock's Absolute Alpha’s AuM topped GBP2bn; Och Ziff’s AuM increased by $2.5bn to $24.8bn; GLG Partners’ AUM was up 6.7% to $23.7bn; Fortress' AuM was down to $30.2bn. And according to Anbima / Bloomberg, Brazilian investors poured 3.4 billion reais ($1.9 billion) into hedge funds last month, the most since December.

Larch Lane Advisors and PineBridge Investments expect to raise an additional $600m by year end for their hedge fund-seeding vehicle; hedge fund industry veterans set up a hedge fund incubator called Lion's Path Capital; Toscafund is considering setting up new business lending capital to banks, and offered mortgage borrowers golden goodbyes; and First Opportunity Fund is to be delisted from the NYSE following its decision to invest in hedge fu......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for